Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Alnylam is a global commercial-stage biopharmaceutical company developing RNAi therapeutics. As of March 31, 2026, the company has six marketed products (four commercialized directly: AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO; two by collaborators: Leqvio, Qfitlia) and over 25 clinical programs. The company achieved profitability for the first time in fiscal year 2025 and continues to execute its "Alnylam 2030" strategy.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $1,167,175 | $594,189 |
| Net Product Revenues | $1,036,127 | $468,538 |
| Net Income (Loss) | $205,991 | $(18,251) |
| Income from Operations | $268,636 | $18,077 |
| Operating Margin | 23.0% | 3.0% |
| Net Cash Provided by Operating Activities | $70,504 | $(120,312) |
| Cash, Cash Equivalents & Marketable Securities | $3,009,223 | $1,022,249 (End of Period Cash Flow) |
| Convertible Debt Outstanding (Principal) | $397,200 | $1,040,000 (Prior to Repurchases) |
Note: Cash, Cash Equivalents & Marketable Securities calculated as sum of Cash ($1,710,779) and Marketable Debt Securities ($1,298,444) from Balance Sheet.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 96% year-over-year, driven primarily by a 121% increase in net product revenues. AMVUTTRA revenues surged 187% to $889.9 million, fueled by the March 2025 FDA approval for ATTR-CM and subsequent global launches.
- Profitability: The company reported net income of $206.0 million compared to a net loss of $18.3 million in Q1 2025. Operating income increased from $18.1 million to $268.6 million.
- Cost of Goods Sold (COGS): COGS increased 196% to $207.5 million, and COGS as a percentage of net product revenues rose to 20.0% (from 15.0%). This is attributed to higher AMVUTTRA sales triggering tiered royalty payments to Sanofi.
- Debt Restructuring: In September and December 2025, the company repurchased approximately $672.2 million of its 2027 Convertible Senior Notes. As of March 31, 2026, $362.8 million of the 2027 Notes remain outstanding, alongside $661.3 million of 2028 Notes issued in September 2025.
- Cash Flow: Operating cash flow turned positive ($70.5 million) compared to a use of cash ($120.3 million) in the prior year, reflecting stronger product sales receipts.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects to sustain profitability and fund operations through product revenues and collaborations. The company anticipates continued investment in R&D for late-stage programs (nucresiran, zilebesiran) and commercial expansion of AMVUTTRA.
- Strategic Milestones:
- Roche Collaboration: Received a $300 million milestone payment in September 2025 for the initiation of the ZENITH Phase 3 trial for zilebesiran.
- Regeneron Collaboration: Regeneron submitted an NDA for cemdisiran (myasthenia gravis) in April 2026.
- Pipeline: Expanded enrollment in the TRITON-CM Phase 3 trial for nucresiran to approximately 1,750 patients.
- Risks and Contingencies:
- Legal Proceedings: Received a subpoena in October 2025 from the U.S. Attorney's Office regarding government price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI. Filed a patent infringement lawsuit against Cipla regarding a generic version of Leqvio in March 2026.
- Regulatory: Received an untitled letter from the FDA in April 2026 regarding consumer-facing website content for AMVUTTRA.
- Financial: Significant exposure to royalty payments on AMVUTTRA sales (tiered up to 30%) and liabilities related to the sale of future royalties (Blackstone Royalties) and development funding (Blackstone Life Sciences).
Investor Verification Checklist
- AMVUTTRA Royalty Impact: Verify the sustainability of gross margins given the tiered royalty structure with Sanofi, which increases as sales volume grows.
- Debt Obligations: Confirm the status of the remaining 2027 Convertible Notes ($362.8M principal) and the terms of the 2028 Notes ($661.3M principal), including conversion triggers and potential dilution.
- Legal Exposure: Monitor the outcome of the U.S. Attorney's Office investigation into price reporting and the patent litigation against Cipla regarding Leqvio.
- Cash Runway: Assess the sufficiency of the $3.0 billion cash and marketable securities position against the high burn rate associated with Phase 3 trials (ZENITH, TRITON) and commercial expansion.
- Collaboration Revenue: Track the timing of future milestone payments from Roche (zilebesiran) and Regeneron (cemdisiran) to ensure revenue visibility.